A5078285344- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Potassium and Related Disorders
- Hemodynamic Monitoring and Therapy
- Asthma and respiratory diseases
- Electrolyte and hormonal disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Blood Pressure and Hypertension Studies
- Pulmonary Hypertension Research and Treatments
- Dialysis and Renal Disease Management
- Cardiovascular and exercise physiology
- Biosimilars and Bioanalytical Methods
- Chronic Kidney Disease and Diabetes
- Nutritional Studies and Diet
- Multiple Myeloma Research and Treatments
- Healthcare Systems and Practices
- Body Composition Measurement Techniques
- Health Education and Validation
- Hormonal Regulation and Hypertension
- Cardiac Health and Mental Health
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Non-Invasive Vital Sign Monitoring
i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto
2020
Centro Hospitalar de Vila Nova de Gaia
2018-2020
Icahn School of Medicine at Mount Sinai
2019
Tongji Hospital
2019
Huazhong University of Science and Technology
2019
Mount Sinai Hospital
2019
Universidade do Porto
2008-2018
Hospital de São João
2007-2011
GTx (United States)
2010
Background: PRM‐151, a recombinant human pentraxin‐2 molecule, prevents and reverses fibrosis in animal models of myelofibrosis (MF) part by targeting differentiation fibrocytes from monocytes. In the first stage two‐stage trial, treatment patients (pts) with primary (PMF), post‐essential thrombocythemia/polycythemia vera (post‐ET/PV) MF PRM‐151 ± ruxolitinib (Rux) was associated decreases bone marrow (BMF), improvements hemoglobin (Hgb) platelets (PLT), reductions transfusions symptoms,...
Since the Randomized Aldactone Evaluation Study (RALES), use of spironolactone is recommended in systolic heart failure (HF) patients that have been New York Heart Association (NYHA) class III or IV. There limited information on use, side effects, and withdrawal rate routine clinical practice.Side effects related to are more common than reported trials.Patients who had moderate severe left ventricular dysfunction (LVSD) under optimized medical therapy were included. We introduced those with...
The prognostic role of C-reactive protein (CRP) in acute heart failure (HF) is not fully understood, and the impact an infectious process its risk-stratification power was previously evaluated.As CRP inflammatory marker, value HF probably different patients with without concurrent infection.We recruited admitted to our hospital due from October 2006 2007. All were given treatment at discretion attending physician. Serum measured discharge 225 patients. We followed for 3 months after assess...
Prognostic implications of diuretics dose are not completely understood. We aim to study the association between diuretic doses and long-term prognosis in patients with chronic stable heart failure (HF).We conducted a retrospective cohort 244 followed at an outpatient HF clinic. Admission criteria were clinical stability previous 3 months optimized medical therapy. Demographic characteristics, clinical, laboratory parameters recorded. Patients for 2 years outcome was defined as all-cause...
<h3>BACKGROUND:</h3> The diagnosis of obstructive lung disease (OLD) based on clinical grounds is challenging. There have been no population-based COPD studies that collected pulmonary function data in Portugal, a country transition between phases 2 and 3 the smoking epidemic. <h3>OBJECTIVE:</h3> To estimate prevalence pattern spirometry representative sample adults from Porto, Portugal. <h3>METHODS:</h3> We conducted health survey 2001 2003, 758 participants ≥ 40 years old had reliable...
Fluctuations in serum creatinine (SCr) during hospitalization may provide additional prognostic value beyond baseline renal function. This study aimed to identify groups of patients with distinct trajectories over hospital stay and assess them terms clinical characteristics short-term mortality. retrospective included 35 853 unique adult admissions a tertiary referral center between January 2012 2016 at least three SCr measurements within the first 9 days stay. Individual courses were...
Objective: To determine the factors associated with resistant hypertension (HTN). Methods: We selected a sample of 96 consecutive patients attending HTN consultation in public hospital. collected data on demographic variables, cardiometabolic diseases, antihypertensive, statins and antithrombotic drugs. Age was grouped less than 65 years or older. Obesity defined as body mass index equal greater to 30. Resistant considered blood pressure above 140/90mmHg last visit spite use 3 more...
Paulo, C.; Pereira, S.; Pinho, E.; Mascarenhas, J.; Silva, L.; Ferreira, Santos, R.; M.; Flores, A.; Vilas-Boas, Brás, V.; Lima, M. J. Author Information
Abstract 2818[][1] Background: Pegylated interferon alpha-2a (Peg INF2a) has been demonstrated to be active therapy for high-risk essential thrombocythemia (ET) and polycythemia vera (PV), as well treatment early myelofibrosis (MF). We retrospectively analyzed the outcomes of Peg INF2a in MPN patients treated outside constraints a clinical trial USA EU. Methods: Clinical records at participating centers, receiving context trial, were response (ET PV by ELN criteria; MF EUNMET IWG-MRT...